Wang L, Zhang M, Zhao K, Yuan X, Zhao H, Liu Y
Front Oncol. 2025; 15:1451130.
PMID: 40046628
PMC: 11881191.
DOI: 10.3389/fonc.2025.1451130.
Zheng F, Zhang S, Chang A, Moon J, Wicha M, Wang S
Int J Biol Sci. 2025; 21(4):1819-1836.
PMID: 39990669
PMC: 11844285.
DOI: 10.7150/ijbs.101025.
Szewczyk A, Rembialkowska N, Saczko J, Daczewska M, Novickij V, Kulbacka J
Biol Res. 2025; 58(1):10.
PMID: 39980072
PMC: 11844013.
DOI: 10.1186/s40659-025-00591-9.
Yang J, Cao J, Sun R, Zhou X, Chen Z, Liu B
Breast Cancer Res. 2025; 27(1):20.
PMID: 39930544
PMC: 11812198.
DOI: 10.1186/s13058-025-01973-3.
Muller L, Fauvet F, Chassot C, Angileri F, Coutant A, Degletagne C
Cancer Cell Int. 2025; 25(1):32.
PMID: 39901189
PMC: 11789407.
DOI: 10.1186/s12935-025-03637-w.
Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in breast cancer.
Yang X, Yang X, Tang H, Chen X, Wang J, Zhao H
Discov Oncol. 2025; 16(1):9.
PMID: 39755992
PMC: 11700959.
DOI: 10.1007/s12672-025-01742-w.
Prospective longitudinal analysis of physiologic MRI-based tumor habitat predicts short-term patient outcomes in IDH-wildtype glioblastoma.
Moon H, Park J, Kim N, Kim N, Park S, Kim Y
Neuro Oncol. 2024; 27(3):841-853.
PMID: 39450860
PMC: 11889713.
DOI: 10.1093/neuonc/noae227.
Reconstruction of cancer marker analysis with holistic anatomical precision implicates heterogeneity development during breast tumor progression.
Ge Z, Wang J, He L, Zhao M, Si Y, Chang S
Discov Oncol. 2024; 15(1):564.
PMID: 39406984
PMC: 11480302.
DOI: 10.1007/s12672-024-01442-x.
Defining precancer: a grand challenge for the cancer community.
Faupel-Badger J, Kohaar I, Bahl M, Chan A, Campbell J, Ding L
Nat Rev Cancer. 2024; 24(11):792-809.
PMID: 39354069
DOI: 10.1038/s41568-024-00744-0.
Prospective longitudinal analysis of imaging-based spatiotemporal tumor habitats in glioblastoma, IDH-wild type: implication in patient outcome using multiparametric physiologic MRI.
Moon H, Park J, Kim N, Kim Y, Song S, Hong C
BMC Cancer. 2024; 24(1):1197.
PMID: 39334005
PMC: 11438318.
DOI: 10.1186/s12885-024-12939-7.
Exploring the association between circulating endothelial protein C receptor and disease activity of rheumatoid arthritis in a pilot study.
Xue M, Lin H, Lynch T, Bereza-Malcolm L, Sinnathurai P, Thomas R
Rheumatol Adv Pract. 2024; 8(3):rkae096.
PMID: 39184533
PMC: 11343369.
DOI: 10.1093/rap/rkae096.
Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease.
Dowling G, Keelan S, Cosgrove N, Daly G, Giblin K, Toomey S
Breast Cancer Res Treat. 2024; 207(3):471-476.
PMID: 39090418
PMC: 11420314.
DOI: 10.1007/s10549-024-07431-6.
Breast Cancer Stem Cells and Tumor Heterogeneity: Characteristics and Therapeutic Strategies.
Romaniuk-Drapala A, Toton E, Taube M, Idzik M, Rubis B, Lisiak N
Cancers (Basel). 2024; 16(13).
PMID: 39001543
PMC: 11240630.
DOI: 10.3390/cancers16132481.
Cancer stem cells: advances in knowledge and implications for cancer therapy.
Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z
Signal Transduct Target Ther. 2024; 9(1):170.
PMID: 38965243
PMC: 11224386.
DOI: 10.1038/s41392-024-01851-y.
Investigating phenotypic plasticity due to toxicants with exposure disparities in primary human breast cells .
Schroeder J, Polemi K, Tapaswi A, Svoboda L, Sexton J, Colacino J
Front Oncol. 2024; 14:1411295.
PMID: 38915368
PMC: 11194339.
DOI: 10.3389/fonc.2024.1411295.
Navigating the Intricacies of Tumor Heterogeneity: An Insight into Potential Prognostic Breast Cancer Biomarkers.
Altriche N, Gallant S, Augustine T, Xulu K
Biomark Insights. 2024; 19:11772719241256798.
PMID: 38895160
PMC: 11185041.
DOI: 10.1177/11772719241256798.
An updated review of immunotherapy in esophageal cancer: PD-L1 footprint.
Yao J, Tan X, Sha Y, Chen Y, Chen R, Shi D
Cent Eur J Immunol. 2024; 49(1):77-90.
PMID: 38812606
PMC: 11130989.
DOI: 10.5114/ceji.2024.139269.
3D Bioprinted Tumor-Stroma Models of Triple-Negative Breast Cancer Stem Cells for Preclinical Targeted Therapy Evaluation.
Gonzalez-Callejo P, Garcia-Astrain C, Herrero-Ruiz A, Henriksen-Lacey M, Seras-Franzoso J, Abasolo I
ACS Appl Mater Interfaces. 2024; 16(21):27151-27163.
PMID: 38764168
PMC: 11145592.
DOI: 10.1021/acsami.4c04135.
Chemoresistance to additive PARP/PI3K dual inhibition in triple-negative breast cancer cell lines is associated with adaptive stem cell-like prevalence.
Petrella P, Chen J, Ravelo G, Cosgrove B
bioRxiv. 2024; .
PMID: 38746322
PMC: 11092486.
DOI: 10.1101/2024.04.28.591568.
Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective.
Danielpour D
Pharmaceuticals (Basel). 2024; 17(4).
PMID: 38675493
PMC: 11054419.
DOI: 10.3390/ph17040533.